Clinical utility of targeted treatments in the management of epithelial ovarian cancer.

about

Clinical utility of targeted treatments in the management of epithelial ovarian cancer.

Item

http://www.wikidata.org/entity/Q36171268

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Clinical utility of targeted treatments in the management of epithelial ovarian cancer.

@ast

Clinical utility of targeted treatments in the management of epithelial ovarian cancer.

@en

type

Item

label

Clinical utility of targeted treatments in the management of epithelial ovarian cancer.

@ast

Clinical utility of targeted treatments in the management of epithelial ovarian cancer.

@en

prefLabel

Clinical utility of targeted treatments in the management of epithelial ovarian cancer.

@ast

Clinical utility of targeted treatments in the management of epithelial ovarian cancer.

@en

P1476

Clinical utility of targeted treatments in the management of epithelial ovarian cancer.

@en

P2093

Cheryl Twu

http://www.w3.org/2001/XMLSchema#string

Ernest S Han

http://www.w3.org/2001/XMLSchema#string

P2860

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

The role of PARP in DNA repair and its therapeutic exploitation

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Cancer statistics, 2010

Global cancer statistics, 2002

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.

P304

233-244

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/BTT.S29356

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-07-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22904615

http://www.w3.org/2001/XMLSchema#string

P932

3421473

http://www.w3.org/2001/XMLSchema#string